Kyowa Hakko Bio succeeded its bio-chemical business from Kyowa Hakko Kogyo and was established in 2008. Kyowa Hakko Kogyo can thus be regarded as the predecessor of Kyowa Hakko Bio.
Kyowa Hakko Kogyo
1949 | Establishment of Kyowa Hakko Kogyo. |
---|---|
1951 | Introduced production technology of Streptomycin, an anti-tubercular drug from US pharmaceutical company Merck & Co. Inc., and succeeded in its mass production. |
1956 | Succeeded in the isolation and commercial mass-production of the anticancer drug MitomycinC. World's first invention of the process of L-Glutamic acid production by fermentation. Pioneered in the major business industry of amino-acid fermentation. |
1958 | Invention of the process of L-Lysine production by fermentation. Release of a plant growth regulator Gibberellin Kyowa (contributed to production of seedless grapes). |
1969 | Establishment of Kyowa Hakko USA. |
1973 | Establishment of Kyowa Hakko Europe. |
1981 | Establishment of the Bio Business Headquarters. |
2005 | Completion of the transition to an operating holding company (Pharmaceuticals and Bio-chemicals are its main pillars). |
2007 | Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group. |
Kyowa Hakko Bio
2008 | Establishment of Kyowa Hakko Bio (succeeded Bio-Chemical business from Kyowa Hakko Kogyo). Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group. |
---|---|
2015 | Completion of Construction for Amino Acid Manufacturing Plant in Thailand |
2019 | Became a direct subsidiary of Kirin Holdings Company, Limited through transfer of shares |